Skip to main content

NIAID Archives

Fauci shares lessons learned during pandemic response with Vanderbilt MPH students

May. 12, 2021—Anthony Fauci, MD, chief medical adviser to President Joe Biden’s administration and director of the National Institute of Allergy and Infectious Diseases (NIAID), recently met virtually with students of Vanderbilt University School of Medicine’s Master of Public Health (MPH) program to answer questions about lessons learned during the pandemic and to share career advice.

Read more


Study finds that regulatory protein prevents signaling that triggers cell death

May. 6, 2021—A protein implicated in neurodegenerative diseases including amyotrophic lateral sclerosis prevents the activation of an innate immune response that leads to cell death, Vanderbilt researchers have discovered.

Read more


Team studies new use for pulmonary hypertension drug

Mar. 25, 2021—An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.

Read more


HIV, diabetes and immune cells in fat

Mar. 18, 2021—In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes.

Read more


Key factors in HIV-1 replication

Feb. 8, 2021—HIV-1, the virus that causes AIDS, exploits inositol phosphates in T cells to aid its own assembly and maturation — suggesting that targeting inositol phosphate binding could inhibit HIV-1 replication.

Read more


Exploiting viral vulnerabilities

Dec. 10, 2020—The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections.

Read more


Study details early events of inflammatory response

Dec. 10, 2020—Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.

Read more


VUMC begins study of second COVID-19 vaccine

Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.

Read more


Preserving gut mucus architecture

Oct. 20, 2020—A new method that keeps microbes and gut cells together will be useful for studies of complex host-microbe interactions and for analysis of clinical specimens.

Read more


Early steps in reovirus replication

Oct. 6, 2020—Conformational change in a reovirus surface protein modulate the virus’s attachment to host cells, Vanderbilt researchers have found.

Read more


Rational vaccine design

Sep. 22, 2020—Understanding immunity generated by smallpox vaccine may hold lessons for COVID-19 vaccine development.

Read more


Probing pathogen antibiotic resistance

Sep. 17, 2020—Understanding how bacteria evolve resistance to antibiotics and host stresses could guide the development of more effective antimicrobial therapeutics.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more